Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034065 (
pulmonary embolism
)
14,979
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Six patients with hairy-cell leukemia were treated with gamma-(IFN-gamma) and alpha-(IFN-alpha-2b) interferon; 3-35 months following splenectomy, treatment was started with 4 X 10(6) U/m2 IFN-gamma sc (iv) every second day for 9-35 weeks. Although the white blood cell counts decreased during therapy from 4.1-49 X 10(9)/l to 1.5-43 X 10(9)/l, no hematological or clinical improvement was obtained. Subsequently (interval 0-13 weeks), IFN-alpha-2b was given at an initial dose of 4 X 10(6) U/m2 sc every second day to all patients. After a treatment period corresponding to that of IFN-gamma administration, a significant hematological improvement was observed in five patients (one early death due to
pulmonary embolism
). At the last follow-up (9-14 months after start of treatment; maintenance therapy, 1 X 10(6) U every second day), these patients exhibited normal peripheral blood cell counts, and in bone marrow biopsy specimens a marked decrease of hairy cells was seen (1 CR, 3 PR, 1 MR). Adverse reactions including fever, headache, nausea, dryness of the mouth, myalgia, and fatigue did not significantly differ between the two interferon preparations. Whereas IFN-gamma is unlikely to have any significant impact on the course of
hairy cell leukemia
, IFN-alpha-2b does result in improvement of hematological values and well-being in almost all patients.
...
PMID:[Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia]. 311 51
We report the case of a woman splenectomized to treat her
hairy cell leukemia
(at the moment in remission) 11 years before the detection of neutropenia. The neutropenia began just after the treatment of
pulmonary embolism
by acenocoumarol. The neutropenia disappeared quickly after substitution of acenocoumarol by fluindione. We discuss the attribution of the neutropenia to acenocoumarol and the part played by
hairy cell leukemia
.
...
PMID:[Neutropenia caused by acenocoumarol associated with hairy cell leukemia]. 793 59
We present a young woman who was diagnosed as primary antiphospholipid syndrome (deep vein thrombosis and
pulmonary embolism
in 1999; moderate thrombocytopenia with high-positive anticardiolipin ELISA tests in 2002, and cerebral thrombosis in 2003), and then developed
hairy cell leukemia
(massive splenomegaly, neutropenia, hairy cells in blood smear and bone marrow trephine biopsy in 2004). A partial remission was achieved with interferon-alpha 2a therapy. After the initiation of 2-chloro-deoxyadenosine therapy, splenomegaly disappeared, the percentage of hairy cells on the bone marrow reduced below 1%, platelet count returned to normal levels. After complete remission was achieved for
hairy cell leukemia
proved by bone marrow trephine biopsy, antiphospholipid antibodies were found to be negative, and no further thromboembolic complications and thrombocytopenia were seen. In our literature search, we found only six cases that had both antiphospholipid antibodies and
hairy cell leukemia
. Our case is the first case of antiphospholipid syndrome before the development of
hairy cell leukemia
. Both
hairy cell leukemia
and antiphospholipid syndrome responded to lymphocytotoxic treatment with 2-chloro-deoxyadenosine.
...
PMID:Development of hairy cell leukemia in a patient with antiphospholipid syndrome. 1743 36